Skip to main content
. Author manuscript; available in PMC: 2011 Apr 6.
Published in final edited form as: Cancer Treat Res. 2010;156:403–412. doi: 10.1007/978-1-4419-6518-9_31

Table 31.1.

Risk of permanent amenorrhea after chemotherapy and radiotherapy. Adapted from Lee et al. [1]

Degree of risk Treatment
High risk (>80%)

  • Hematopoietic stem cell transplantation with cyclophoshamide/total body irradiation or cyclophosphamide/busulfan

  • External beam radiation to a field that includes the ovaries

  • CMF, CEF, CAF × 6 cycles in women age 40 and older
Intermediate risk

  • CMF, CEF, CAF × 6 cycles in women age 30–39

  • AC × 4 in women age 40 and older
Lower risk (<20%)

  • CHOP × 4–6 cycles

  • CVP

  • AML therapy (anthracycline/cytarabine)

  • ALL therapy (multi-agent)

  • CMF, CEF, CAF × 6 cycles in women age less than 30
Very low or no risk

  • Vincristine

  • Methotrexate

  • 5-Fluorouracil
Unknown effects

  • Taxanes

  • Oxaliplatin

  • Irinotecan

  • Monoclonal antibodies

  • Tyrosine kinase inhibitors